Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy

Clinical Cardiology

Volumn 33, Issue 2, 2010, Pages

  Kubo, Toru ^a   Kitaoka, Hiroaki ^a   Okawa, Makoto ^a   Yamanaka, Shigeo ^a   Hirota, Takayoshi ^a   Hoshikawa, Eri ^a   Hayato, Kayo ^a   Yamasaki, Naohito ^a   Matsumura, Yoshihisa ^a   Yasuda, Nobufumi ^a   Sugiura, Tetsuro ^a   Doi, Yoshinori L ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TROPONIN I;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE CLASSIFICATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART LEFT VENTRICLE DYSFUNCTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART LEFT VENTRICLE SIZE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SEX DIFFERENCE; SYSTOLIC DYSFUNCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; CHI-SQUARE DISTRIBUTION; CHILD; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEMODYNAMICS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SEX FACTORS; TROPONIN I; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING; YOUNG ADULT;

EID: 77649262003     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20622     Document Type: Article

References (16)

1. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001;103:369-374.
2. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833-838.
3. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775-785.
4. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320.
5. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-1785.
6. Biagini E, Coccolo F, Ferlito M, et al.Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors and prognostic implications in pediatric and adult patients. J Am Coll Cardiol. 2005;46:1543-1550.
7. Petersen SE, Jerosch-Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy; new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115:2418-2425.
8. Thaman R, Esteban MT, Barnes S, et al. Usefulness of Nterminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2006;98:515-519.
9. Maron BJ. Tholakanahalli VN, Zenovich AG, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004;109:984-989.
10. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476-482.
11. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216-225.
12. Nakamura T, Sakamoto K, Yamano T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41:315-321.
13. Takeuchi I, Inomata T, Nishii M, et al. Clinical characteristics of heart disease patients with a good prognosis in spite of markedly increased plasma levels of type-B natriuretic peptide (BNP); anomalous behavior of plasma BNP in hypertrophic cardiomyopathy. Circ J. 2005;69:277-282.
14. Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, BasaranY. Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2006;98:1504-1506.
15. Pieroni M, Bellocci F, Sanna T, et al. Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Cardiac Fail. 2007;13:380-388.
16. Perna ER,Macin SM,Cimbaro JP, et al.Ongoingmyocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation. 2004;110:2376-2382.